Literature DB >> 35672074

Rehabilitation using virtual gaming for Hospital and hOMe-Based training for the Upper limb post Stroke (RHOMBUS II): protocol of a feasibility randomised controlled trial.

Cherry Kilbride1, Alyson Warland2, Victoria Stewart3, Basaam Aweid4,5, Arul Samiyappan6, Jennifer Ryan2,7, Tom Butcher2, Dimitrios A Athanasiou8, Karen Baker8, Guillem Singla-Buxarrais8, Nana Anokye2, Carole Pound9, Francesca Gowing2, Meriel Norris2.   

Abstract

INTRODUCTION: Upper limb (UL) rehabilitation is most effective early after stroke, with higher doses leading to improved outcomes. For the stroke survivor, the repetition may be monotonous. For clinicians, providing a clinically meaningful level of input can be challenging. As such, time spent engaged in UL activity among subacute stroke survivors remains inadequate. Opportunities for the stroke survivor to engage with UL rehabilitation in a safe, accessible and engaging way are essential to improving UL outcomes following stroke. The NeuroBall is a non-immersive virtual reality (VR) digital system designed for stroke rehabilitation, specifically for the arm and hand. The aim of the Rehabilitation using virtual gaming for Hospital and hOMe-Based training for the Upper limb post Stroke study is to determine the safety, feasibility and acceptability of the NeuroBall as a rehabilitation intervention for the UL in subacute stroke. METHODS AND ANALYSIS: A feasibility randomised controlled trial (RCT) will compare the NeuroBall plus usual care with usual care only, in supporting UL rehabilitation over 7 weeks. Twenty-four participants in the subacute poststroke phase will be recruited while on the inpatient or early supported discharge (ESD) stroke pathway. Sixteen participants will be randomised to the intervention group and eight to the control group. Outcomes assessed at baseline and 7 weeks include gross level of disability, arm function, spasticity, pain, fatigue and quality of life (QoL). Safety will be assessed by recording adverse events and using pain, spasticity and fatigue scores. A parallel process evaluation will assess feasibility and acceptability of the intervention. Feasibility will also be determined by assessing fidelity to the intervention. Postintervention, semistructured interviews will be used to explore acceptability with 12 participants from the intervention group, four from the usual care group and with up to nine staff involved in delivering the intervention. ETHICS AND DISSEMINATION: This trial has ethical approval from Brunel University London's Research Ethics Committee 25257-NHS-Oct/2020-28121-2 and the Wales Research Ethics Committee 5 Bangor (Health and Care Research Wales) REC ref: 20/WA/0347. The study is sponsored by Brunel University London. CONTACT: Dr Derek Healy, Chair, University Research Ethics committee (Derek.healy@brunel.ac.uk). Trial results will be submitted for publication in peer-reviewed journals, presented at national and international conferences and distributed to people with stroke. TRIAL REGISTRATION NUMBER: ISRCTN11440079; Pre-results. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  NEUROLOGY; REHABILITATION MEDICINE; Stroke

Mesh:

Year:  2022        PMID: 35672074      PMCID: PMC9174817          DOI: 10.1136/bmjopen-2021-058905

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   3.006


  38 in total

1.  The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency.

Authors:  Julius Sim; Martyn Lewis
Journal:  J Clin Epidemiol       Date:  2011-12-09       Impact factor: 6.437

2.  The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance.

Authors:  A R Fugl-Meyer; L Jääskö; I Leyman; S Olsson; S Steglind
Journal:  Scand J Rehabil Med       Date:  1975

Review 3.  Motor recovery after stroke: a systematic review.

Authors:  Peter Langhorne; Fiona Coupar; Alex Pollock
Journal:  Lancet Neurol       Date:  2009-08       Impact factor: 44.182

4.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Authors:  Ben van Hout; M F Janssen; You-Shan Feng; Thomas Kohlmann; Jan Busschbach; Dominik Golicki; Andrew Lloyd; Luciana Scalone; Paul Kind; A Simon Pickard
Journal:  Value Health       Date:  2012-05-24       Impact factor: 5.725

5.  Recovery of upper limb dexterity in patients more than 1 year after stroke: Frequency, clinical correlates and predictors.

Authors:  Keng-He Kong; Karen S G Chua; Jeanette Lee
Journal:  NeuroRehabilitation       Date:  2011       Impact factor: 2.138

6.  Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation.

Authors:  Poyu Chen; Keh-Chung Lin; Rong-Jiuan Liing; Ching-Yi Wu; Chia-Ling Chen; Ku-Chou Chang
Journal:  Qual Life Res       Date:  2015-11-30       Impact factor: 4.147

7.  Interrater reliability of the Modified Modified Ashworth Scale (MMAS) for patients with wrist flexor muscle spasticity.

Authors:  Soofia Naghdi; Noureddin Nakhostin Ansari; Somayye Azarnia; Anoushiravan Kazemnejad
Journal:  Physiother Theory Pract       Date:  2008 Sep-Oct       Impact factor: 2.279

8.  Randomized controlled trial of an early discharge rehabilitation service: the Belfast Community Stroke Trial.

Authors:  Michael Donnelly; Michael Power; Mary Russell; Ken Fullerton
Journal:  Stroke       Date:  2003-12-11       Impact factor: 7.914

9.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

10.  Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework.

Authors:  Mandeep Sekhon; Martin Cartwright; Jill J Francis
Journal:  BMC Health Serv Res       Date:  2017-01-26       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.